Phase I and II drug metabolizing enzymes (DME) and drug transporters are involved in the
absorption, distribution, metabolism as well as elimination of many therapeutic agents …

Objectives We evaluated the importance of ethnicity and pharmacogenetic variations in
determining efavirenz pharmacokinetics, auto-induction and immunological outcomes in two …

One of the ongoing issues in perinatal medicine is the risk of birth defects associated with
maternal drug use. The teratogenic effect of a drug depends, apart from other factors, on the …

Myrcludex B acts as a hepatitis B and D virus entry inhibitor blocking the sodium
taurocholate cotransporting polypeptide (SLC10A1). We investigated the effects of …

Purpose Recent studies reported the association of SLCO1B1 haplotypes with the
development of musculoskeletal side effects during simvastatin use. The aim was to …

Objectives To investigate the timing, incidence, clinical presentation, pharmacokinetics and
pharmacogenetic predictors for antiretroviral and anti-tuberculosis drug induced liver injury …

Background Drug-induced liver injury (DILI) is a well-recognized adverse event of anti
tuberculosis drugs (ATD) possibly associated with genetic variations. The objective of this …

Pharmacogenomics may improve patient care by guiding drug selection and dosing;
however, this requires prior knowledge of the pharmacogenomics of drugs commonly used …

Background Recent studies reported the association between SLCO1B1 polymorphisms
and the development of statin-induced myopathy. In the scenario of the Brazilian population …

Introduction: Bulevirtide is a first-in-class antiviral drug to treat chronic hepatitis B/D. We
investigated the drug-drug interaction potential and pharmacokinetics of high-dose …